High frequency of BRAF mutations in nevi
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
To evaluate the timing of mutations in BRAF (v-raf murine sarcoma viral oncogene homolog B1) during melanocytic neoplasia, we carried out mutation analysis on microdissected melanoma and nevi samples. We observed mutations resulting in the V599E amino-acid substitution in 41 of 60 (68%) melanoma metastases, 4 of 5 (80%) primary melanomas and, unexpectedly, in 63 of 77 (82%) nevi. These data suggest that mutational activation of the RAS/RAF/MAPK pathway in nevi is a critical step in the initiation of melanocytic neoplasia but alone is insufficient for melanoma tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, the BRAF oncogenic mutation found in more than half of all malignant cutaneous melanomas is commonly found also in non-malignant nevi, where it causes oncogene-induced senescence exemplified by high levels of CDKN2A and SA-β-gal expression225–227.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [226]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Busca, R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.12.2900 · Cited by 326
The Regulation of Normal Melanocyte Proliferation
Halaban, R. (2000) · Pigment Cell Research · doi:10.1034/j.1600-0749.2000.130103.x · Cited by 179
Research works printed but not linked: 2
- Armstrong, B.K. & English, D.R. in Cancer Epidemiology and Prevention (Oxford University Press, New York, 1996).
- Elder, D.E. & Murphy, G.F. in Atlas of Tumor Pathology: Melanocytic Tumors of the Skin 5–101 (Armed Forces Insititute of Pathology, Washington, DC, 1991).
Cited by
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
“As in previous reports (Pollock et al., 2003), both BRAF V600 and K601 Cell 161, 1681–1696, June 18, 2015 ª2015 Elsevier Inc. 1683 Prominent mechanisms of pathway alterations in BRAF, RAS, NF1 and Triple Wild-Type (WT) subtypes with potential predictive genetic alterations indicated (1, 2, 3, 4, 5,…”
ResultInfluentialSelf-citationMAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
“The existence of suppressors of mutant B-Raf is suggested by the finding that >80% of benign naevi contain oncogenic B-Raf mutations without ever progressing to melanoma (Pollock et al., 2003).”
BackgroundDistinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
The essence of senescence: Figure 1.
Kuilman, T., Michaloglou, C., Mooi, W. J., & Peeper, D. S. (2010) · Genes & Development · doi:10.1101/gad.1971610 · Cited by 2,038
“At least as remarkable was the finding that the same mutation is present in the large majority of nevi (Pollock et al. 2003).”
BackgroundClinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Van Raamsdonk, C. D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O’Brien, J. M., Simpson, E. M., Barsh, G. S., & Bastian, B. C. (2009) · Nature · doi:10.1038/nature07586 · Cited by 1,623
“The majority of nevi and melanomas show oncogenic mutations in signaling components of the MAP kinase pathway, in particular BRAF and NRAS 1,2.”
BackgroundHyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
“The V600E mutation is also detected in a large percentage of nevi, which are benign skin lesions of melanocytes that are thought to be senescen”
BackgroundMutations in GNA11 in Uveal Melanoma
Van Raamsdonk, C. D., Griewank, K. G., Crosby, M. B., Garrido, M. C., Vemula, S., Wiesner, T., Obenauf, A. C., Wackernagel, W., Green, G., Bouvier, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000584 · Cited by 1,476
Melanoma biology and new targeted therapy
Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007) · Nature · doi:10.1038/nature05661 · Cited by 1,371
“One intriguing observation is that BRAF is mutated in up to 80p of benign naev”
BackgroundDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
“Note that certain premalignant cells such as those found in benign nevi also demonstrate frequent expression of B-RafV600E (20, 21), and it remains unclear how these cells avoid transformation to a malignant state.”
BackgroundMiller, A. J., & Mihm, M. C. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052166 · Cited by 1,339
BRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
“…initial discovery, BRAF mutations have now been reported in numerous types of human cancer with various frequencies (Garnett & Marais 2004), being most prevalent in melanomas and nevi, present in 66 and 82% of these dermatologic lesion types, respectively (Davies et al. 2002, Pollock et al. 2003).”
BackgroundERK and cell death: mechanisms of ERK-induced cell death--apoptosis, autophagy and senescence
Cagnol, S., & Chambard, J. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07366.x · Cited by 1,290
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., McCusker, J. P., Cheng, E., Davis, M. J., Goh, G., Choi, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2359 · Cited by 1,191
Self-citationBrafV600E cooperates with Pten loss to induce metastatic melanoma
Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189
Liquid biopsy and minimal residual disease - latest advances and implications for cure
Pantel, K., & Alix-Panabières, C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0187-3 · Cited by 1,110
The Genetic Evolution of Melanoma from Precursor Lesions
Shain, A. H., Yeh, I., Kovalyshyn, I., Sriharan, A., Talevich, E., Gagnon, A., Dummer, R., North, J., Pincus, L., Ruben, B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502583 · Cited by 1,065
The signals and pathways activating cellular senescence
Ben-Porath, I., & Weinberg, R. A. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.10.013 · Cited by 1,046
“T than i ayer t itt for i a it is e gress tion p ctiv t s to t as a w to d ribuepresent a general case of in vivo oncogene-ind enescence (Bennett, 2003; Pollock et al., 2003).”
BackgroundSenescence-messaging secretome: SMS-ing cellular stress
Kuilman, T., & Peeper, D. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2560 · Cited by 909
“In human melanocytic naevus cells (which often express BRAF E600 (Ref”
BackgroundWajapeyee, N., Serra, R. W., Zhu, X., Mahalingam, M., & Green, M. R. (2008) · Cell · doi:10.1016/j.cell.2007.12.032 · Cited by 903
“Activating BRAF mutations are also present in up to 82% of melanocytic nevi (Pollock et al., 2003), which are benign skin lesions that rarely progress to melanoma (Bennett, 2003; Chin et al.”
Shain, A. H., & Bastian, B. C. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.37 · Cited by 896
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Holderfield, M., Deuker, M. M., McCormick, F., & McMahon, M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3760 · Cited by 833
Vemurafenib: the first drug approved for BRAF-mutant cancer
Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., & Hirth, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3847 · Cited by 822
Garnett, M. J., & Marais, R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.022 · Cited by 799
Early dissemination seeds metastasis in breast cancer
Hosseini, H., Obradović, M. M. S., Hoffmann, M., Harper, K. L., Sosa, M. S., Werner-Klein, M., Nanduri, L. K., Werno, C., Ehrl, C., Maneck, M., et al. (2016) · Nature · doi:10.1038/nature20785 · Cited by 740
“Strongly oncogenic mutations characterize benign tumours that do not metastasize 36–38 ; indeed, strong activation of oncogenic pathways represses metastasis while increasing proliferation 39,40 .”
Epidemiology of Melanoma and Nonmelanoma Skin Cancer—The Role of Sunlight
Leiter, U., & Garbe, C. (2009) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-77574-6_8 · Cited by 717
BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum
Kambara, T., Simms, L. A., Whitehall, V. L. J., Spring, K. J., Wynter, C. V. A., Walsh, M. D., Barker, M. A., Arnold, S., McGivern, A., Matsubara, N., et al. (2004) · Gut · doi:10.1136/gut.2003.037671 · Cited by 722
“11 13 In extraintestinal tumours, BRAF mutations also appear to occur early in tumorigenesis, for example in naevi, 49 and in specific subgroups, for example serous borderline tumours which are precursors of low grade ovarian serous carcinomas.”
BackgroundJAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis
Steelman, L. S., Pohnert, S. C., Shelton, J. G., Franklin, R. A., Bertrand, F. E., & McCubrey, J. A. (2004) · Leukemia · doi:10.1038/sj.leu.2403241 · Cited by 684
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC
Soares, P., Trovisco, V., Rocha, A. S., Lima, J., Castro, P., Preto, A., Máximo, V., Botelho, T., Seruca, R., & Sobrinho-Simões, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206706 · Cited by 679
Melanoma epidemiology and trends
Garbe, C., & Leiter, U. (2009) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2008.09.001 · Cited by 657
Patton, E. E., Widlund, H. R., Kutok, J. L., Kopani, K. R., Amatruda, J. F., Murphey, R. D., Berghmans, S., Mayhall, E. A., Traver, D., Fletcher, C. D. M., et al. (2005) · Current Biology · doi:10.1016/j.cub.2005.01.031 · Cited by 664
Karreth, F. A., Tay, Y., Perna, D., Ala, U., Tan, S. M., Rust, A. G., DeNicola, G., Webster, K. A., Weiss, D., Perez-Mancera, P. A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.032 · Cited by 653
“Indeed, 80% of human nevi harbor a BRAF mutation (Pollock et al., 2003).”
Leiter, U., Eigentler, T., & Garbe, C. (2014) · Sunlight, Vitamin D and Skin Cancer · doi:10.1007/978-1-4939-0437-2_7 · Cited by 574
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness
Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K. S., Testori, A., Larue, L., & Goding, C. R. (2006) · Genes & Development · doi:10.1101/gad.406406 · Cited by 608
“Consistent with the notion discussed by Bernards and Weinberg (2002) that prometastatic genes could in fact be those oncogenes that are activated early in the transformation process, gain of function mutations in BRAF that are acquired early in melanomagenesis (Pollock et al. 2003) strongly down-regulate Mitf expressi…”
BackgroundCutaneous melanoma: From pathogenesis to therapy (Review)
Leonardi, G., Falzone, L., Salemi, R., Zangh�, A., Spandidos, D., Mccubrey, J., Candido, S., & Libra, M. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4287 · Cited by 588
“An interesting finding is that BRAF is mutated in up to 80% of benign nevi, resulting in limited melanocyte proliferation through the oncogene-mediated activation of cell senescence (34,35).”
Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice
Dhomen, N., Reis-Filho, J. S., da Rocha Dias, S., Hayward, R., Savage, K., Delmas, V., Larue, L., Pritchard, C., & Marais, R. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.022 · Cited by 594
“Furthermore, BRAFV600E mutations are found in up to 80% of human nevi, benign melanocytic lesions that can remain unchanged for decades (Pollock et al., 2003), and BRAFV600E induces classical oncogene-induced senescence in human melanocytes in vitro (Gray-Schopfer et al., 2006; Michaloglou et al.,…”
BackgroundInfluentialGermline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome
Rodriguez-Viciana, P., Tetsu, O., Tidyman, W. E., Estep, A. L., Conger, B. A., Cruz, M. S., McCormick, F., & Rauen, K. A. (2006) · Science · doi:10.1126/science.1124642 · Cited by 571
Deep Visual Proteomics defines single-cell identity and heterogeneity
Mund, A., Coscia, F., Kriston, A., Hollandi, R., Kovács, F., Brunner, A.-D., Migh, E., Schweizer, L., Santos, A., Bzorek, M., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01302-5 · Cited by 562
Hoek, K. S., Schlegel, N. C., Brafford, P., Sucker, A., Ugurel, S., Kumar, R., Weber, B. L., Nathanson, K. L., Phillips, D. J., Herlyn, M., et al. (2006) · Pigment Cell Research · doi:10.1111/j.1600-0749.2006.00322.x · Cited by 555
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset
Ceol, C. J., Houvras, Y., Jane-Valbuena, J., Bilodeau, S., Orlando, D. A., Battisti, V., Fritsch, L., Lin, W. M., Hollmann, T. J., Ferré, F., et al. (2011) · Nature · doi:10.1038/nature09806 · Cited by 542
Lysosome-mediated processing of chromatin in senescence
Ivanov, A., Pawlikowski, J., Manoharan, I., van Tuyn, J., Nelson, D. M., Rai, T. S., Shah, P. P., Hewitt, G., Korolchuk, V. I., Passos, J. F., et al. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201212110 · Cited by 539
“For example, virtually all benign human nevi harbor activating mutations in N-RAS or its downstream effector, BRAF (Omholt et al., 2002; Pollock et al., 2003; GraySchopfer et al., 2007).”
Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers
Namba, H., Nakashima, M., Hayashi, T., Hayashida, N., Maeda, S., Rogounovitch, T. I., Ohtsuru, A., Saenko, V. A., Kanematsu, T., & Yamashita, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030305 · Cited by 533
“The frequency of BRAF mutations varies widely in human cancers from more than 80% in melanomas and nevi (9, 10), to as little as 0–18% in other tumors, such as 1–3% in lung cancers and 5% in colorectal cancers (11–13).”
BackgroundThe Molecular Pathology of Melanoma: An Integrated Taxonomy of Melanocytic Neoplasia
Bastian, B. C. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104658 · Cited by 513
Malignant melanoma: genetics and therapeutics in the genomic era
Chin, L., Garraway, L. A., & Fisher, D. E. (2006) · Genes & Development · doi:10.1101/gad.1437206 · Cited by 511
“2002), mutations in BRAF have been detected in a variety of tumor types, with the highest incidence in melanoma (ranging from 27% to 70%) (Maldonado et al. 2003; Pollock et al. 2003; Uribe et al. 2003; Daniotti et al. 2004; Kumar et al. 2004; Shinozaki et al. 2004; Libra et al. 2005), followed by papillary thyroid tum…”
BackgroundInfluentialO'Brien, M. J., Yang, S., Mack, C., Xu, H., Huang, C. S., Mulcahy, E., Amorosino, M., & Farraye, F. A. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213313.36306.85 · Cited by 509
“BRAF mutations were assayed by allele-specific PCR (AS-PCR) (codon V600E) and validated in a sample of 50 selected cases by direct sequencing of exon 15 as previously described.(31,45) MSI-PCR was performed with fluorescent-labeled primers for BAT25 and BAT26,(4,47) and capillary electrophoresis was performed using an…”
MethodMelanoma: from mutations to medicine
Tsao, H., Chin, L., Garraway, L. A., & Fisher, D. E. (2012) · Genes & Development · doi:10.1101/gad.191999.112 · Cited by 496
“…BRAF mutations—most commonly a valine-toglutamic acid substitution at codon 600—have been observed in ;50% of melanomas (Maldonado et al. 2003; Pollock et al. 2003b; Uribe et al. 2003; Daniotti et al. 2004; Kumar et al. 2004; Shinozaki et al. 2004; Libra et al. 2005) and to a lesser extent…”
Dankort, D., Filenova, E., Collado, M., Serrano, M., Jones, K., & McMahon, M. (2007) · Genes & Development · doi:10.1101/gad.1516407 · Cited by 481
“PD0325901 displays a nanomolar IC50 in cells and, unlike most protein kinase inhibitors, acts noncompetitively with its substrates (Sebolt-Leopold and Herrera 2004).”
BackgroundBRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
Colombino, M., Capone, M., Lissia, A., Cossu, A., Rubino, C., De Giorgi, V., Massi, D., Fonsatti, E., Staibano, S., Nappi, O., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.2452 · Cited by 471
Capper, D., Preusser, M., Habel, A., Sahm, F., Ackermann, U., Schindler, G., Pusch, S., Mechtersheimer, G., Zentgraf, H., & von Deimling, A. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0841-z · Cited by 472
“Particularly high BRAF V600E mutation rates have been detected in melanoma (*30–70%), papillary thyroid carcinoma (40–70%), pleomorphic xanthoastrocytomas (*60–70%), and Langerhans cell histiocytosis (*50–60%), and in some benign lesions, for example melanocytic nevi and serrated polyps of the large intestine [5, 11,…”
BackgroundGenetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma
Tsao, H., Yang, G., Goel, V., Wu, H., & Haluska, F. G. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.22243.x · Cited by 467
“Moreover, BRAF, which is a component of the RAS/RAF/MAPK signaling cassette, was recently found to be mutated in 60% to 80% of cutaneous melanomas and benign melanocytic nevi (Davies et al, 2002; Pollock et al, 2003).”
BackgroundDazert, E., & Hall, M. N. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.09.003 · Cited by 460
Smalley, K. S. M., Haass, N. K., Brafford, P. A., Lioni, M., Flaherty, K. T., & Herlyn, M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0084 · Cited by 463
“The finding that there are V600E BRAF mutations in nontumorigenic melanocytic nevi (18) then lacking in early-stage radial growth phase melanomas, only to appear at the later vertical growth phase melanomas (19), is difficult to interpret and requires further study.”
BackgroundAdnane, L., Trail, P. A., Taylor, I., & Wilhelm, S. M. (2006) · Methods in Enzymology · doi:10.1016/s0076-6879(05)07047-3 · Cited by 463
Raf proteins and cancer: B-Raf is identified as a mutational target
Mercer, K. E., & Pritchard, C. A. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00016-7 · Cited by 457
New insights into the generation and role of de novo mutations in health and disease
Acuna-Hidalgo, R., Veltman, J. A., & Hoischen, A. (2016) · Genome Biology · doi:10.1186/s13059-016-1110-1 · Cited by 453
“For instance, the same genetic alteration in genes in the RAS–MAPK pathway can result in very diverse phenotypes, depending on the timing at which they arise [164, 170, 171].”
Autophagy Sustains Mitochondrial Glutamine Metabolism and Growth of Braf V600E–Driven Lung Tumors
Strohecker, A. M., Guo, J. Y., Karsli-Uzunbas, G., Price, S. M., Chen, G. J., Mathew, R., McMahon, M., & White, E. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0397 · Cited by 435
The gene expression signatures of melanoma progression
Haqq, C., Nosrati, M., Sudilovsky, D., Crothers, J., Khodabakhsh, D., Pulliam, B. L., Federman, S., Miller, J. R., Allen, R. E., Singer, M. I., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501564102 · Cited by 433
High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu, X., Quiros, R. M., Gattuso, P., Ain, K. B., & Prinz, R. A. (2003) · PubMed · Cited by 415
Strumberg, D., Clark, J. W., Awada, A., Moore, M. J., Richly, H., Hendlisz, A., Hirte, H. W., Eder, J. P., Lenz, H.-J., & Schwartz, B. (2007) · The Oncologist · doi:10.1634/theoncologist.12-4-426 · Cited by 419
“V600E mutations have also been reported in a relatively high proportion (82%) of nevi [ 22 ].”
Cheng, L., Lopez-Beltran, A., Massari, F., MacLennan, G. T., & Montironi, R. (2018) · Modern Pathology · doi:10.1038/modpathol.2017.104 · Cited by 407
SenNet recommendations for detecting senescent cells in different tissues
Suryadevara, V., Hudgins, A. D., Rajesh, A., Pappalardo, A., Karpova, A., Dey, A. K., Hertzel, A., Agudelo, A., Rocha, A., Soygur, B., et al. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00738-8 · Cited by 408
Suppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M., & Tuveson, D. A. (2003) · PubMed · Cited by 455
Yang, H., Higgins, B., Kolinsky, K., Packman, K., Go, Z., Iyer, R., Kolis, S., Zhao, S., Lee, R., Grippo, J. F., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0646 · Cited by 407
Cellular senescence in naevi and immortalisation in melanoma: a role for p16?
Gray-Schopfer, V. C., Cheong, S. C., Chong, H., Chow, J., Moss, T., Abdel-Malek, Z. A., Marais, R., Wynford-Thomas, D., & Bennett, D. C. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603283 · Cited by 394
Omholt, K., Platz, A., Kanter, L., Ringborg, U. K., & Hansson, J. (2003) · PubMed · Cited by 399
Somatic mutations in the PTCH,SMOH,SUFUH and TP53 genes in sporadic basal cell carcinomas
Reifenberger, J., Wolter, M., Knobbe, C. B., Köhler, B., Schönicke, A., Scharwächter, C., Kumar, K., Blaschke, B., Ruzicka, T., & Reifenberger, G. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06353.x · Cited by 399
Examination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melanoma
Goel, V. K., Lazar, A. J. F., Warneke, C. L., Redston, M. S., & Haluska, F. G. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700026 · Cited by 392
“Most melanocytic nevi do not progress to melanoma (Omholt et al., 2003; Pollock et al., 2003; Uribe et al., 2003; Yazdi et al., 2003; Saldanha et al., 2004).”
BackgroundRaf Family Kinases: Old Dogs Have Learned New Tricks
Matallanas, D., Birtwistle, M., Romano, D., Zebisch, A., Rauch, J., von Kriegsheim, A., & Kolch, W. (2011) · Genes & Cancer · doi:10.1177/1947601911407323 · Cited by 386
“This is in line with observations from human tumors, where B-Raf V600E is detected in approximately 44% of melanoma cases,(316) but with even higher frequency in benign nevi, which do not progress into a malignant melanoma.(318) This dormancy is probably due to the potent induction of senescence by B-Raf V600E, which…”
ResultPhenotype plasticity as enabler of melanoma progression and therapy resistance
Arozarena, I., & Wellbrock, C. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0154-4 · Cited by 381
Improving Melanoma Classification by Integrating Genetic and Morphologic Features
Viros, A., Fridlyand, J., Bauer, J., Lasithiotakis, K., Garbe, C., Pinkel, D., & Bastian, B. C. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050120 · Cited by 379
“Upward scatter is unlikely to be entirely attributable to BRAF mutations, as scatter is typically absent in nevi, many of which have BRAF mutations [29], suggesting that other genes cooperating with BRAF may be involved.”
Oncogene-Induced Cell Senescence — Halting on the Road to Cancer
Mooi, W. J., & Peeper, D. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062285 · Cited by 371
BRAF mutations are associated with some histological types of papillary thyroid carcinoma
Trovisco, V., Vieira de Castro, I., Soares, P., Máximo, V., Silva, P., Magalhães, J., Abrosimov, A., Guiu, X. M., & Sobrinho‐Simões, M. (2004) · The Journal of Pathology · doi:10.1002/path.1511 · Cited by 363
“The results on record show that after melanoma, in which the mutation is found in up to 70% of cases [7–9], PTC is the human cancer displaying the highest prevalence of BRAF mutation.”
BackgroundCongenital Melanocytic Nevi Frequently Harbor NRAS Mutations but no BRAF Mutations
Bauer, J., Curtin, J. A., Pinkel, D., & Bastian, B. C. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700490 · Cited by 351
Denoyelle, C., Abou-Rjaily, G., Bezrookove, V., Verhaegen, M., Johnson, T. M., Fullen, D. R., Pointer, J. N., Gruber, S. B., Su, L. D., Nikiforov, M. A., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1471 · Cited by 349
“This incidence is, however, relatively low considering that nearly all individuals of fair skin bear an average of 10–40 putative precursor lesions (naevi or 'moles'), most of which express pro-oncogenic mutations in the mitogen-activated protein kinase (MAPK) pathway (frequently in BRAF or RAS genes”
BackgroundOncogenic Mutations in GNAQ Occur Early in Uveal Melanoma
Onken, M. D., Worley, L. A., Long, M. D., Duan, S., Council, M. L., Bowcock, A. M., & Harbour, J. W. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2145 · Cited by 346
“For example, BRAF mutations occur very early in cutaneous melanoma, and are even present in benign and premalignant nevi.(34,35) Similarly, the absence of correlation between GNAQ mutation and clinical, pathologic, immunohistochemical, and genetic indicators of tumor progression, and the presence of the mutation in tu…”
BackgroundKinsler, V. A., Thomas, A. C., Ishida, M., Bulstrode, N. W., Loughlin, S., Hing, S., Chalker, J., McKenzie, K., Abu-Amero, S., Slater, O., et al. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.70 · Cited by 348
“, 2011), BRAF (Papp et al., 1999; Pollock et al., 2003; Kumar et al., 2004; Papp et al., 2005; Ichii-Nakato et al., 2006; Dessars et al., 2007; Adjei et al., 2008), and TP53 (Papp et al.”
InfluentialV599EB-RAF is an Oncogene in Melanocytes
Wellbrock, C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., Niculescu-Duvaz, D., Springer, C. J., & Marais, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3433 · Cited by 344
“Clearly, B-RAF is not sufficient to induce melanoma because B-RAF is mutated in a high proportion of nevi (6, 8).”
BackgroundThompson, J. F., Scolyer, R. A., & Kefford, R. F. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17951-3 · Cited by 292
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
Moding, E. J., Nabet, B. Y., Alizadeh, A. A., & Diehn, M. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0634 · Cited by 325
Raf kinases: Function, regulation and role in human cancer
Leicht, D. T., Balan, V., Kaplun, A., Singh-Gupta, V., Kaplun, L., Dobson, M., & Tzivion, G. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.05.001 · Cited by 317
BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas.
Chan, T. L., Zhao, W., Leung, S. Y., & Yuen, S. T. (2003) · PubMed · Cited by 319
Mutant V599EB-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors
Sharma, A., Trivedi, N. R., Zimmerman, M. A., Tuveson, D. A., Smith, C. D., & Robertson, G. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2423 · Cited by 321
“Mutations that lead to activation of B-Raf have been found in the majority of sporadic melanomas, making B-RAF the most mutated gene in melanomas with a mutation rate ranging from 60% to 90% (5, 7 , 18, 19).”
BackgroundEdlundh-Rose, E., Egyha??zi, S., Omholt, K., Mansson-Brahme, E., Platz, A., Hansson, J., & Lundeberg, J. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000232300.22032.86 · Cited by 318
Ackermann, J., Frutschi, M., Kaloulis, K., McKee, T., Trumpp, A., & Beermann, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2970 · Cited by 306
“Mutations affecting the serine/threonine kinase B-Raf are equally often found in melanoma, melanocytic nevi, and metastases (17).”
Grbovic, O. M., Basso, A. D., Sawai, A., Ye, Q., Friedlander, P., Solit, D., & Rosen, N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609973103 · Cited by 308
BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.
Dong, J., Phelps, R. G., Qiao, R., Yao, S., Benard, O., Ronai, Z. A., & Aaronson, S. A. (2003) · PubMed · Cited by 340
Raf: A Strategic Target for Therapeutic Development Against Cancer
Beeram, M., Patnaik, A., & Rowinsky, E. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.036 · Cited by 298
The genetics of malignant melanoma: lessons from mouse and man
Chin, L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1145 · Cited by 302
“More recently, BRAF mutations have also been shown to be common in benign and dysplastic nev”
BackgroundHouben, R., Becker, J. C., Kappel, A., Terheyden, P. A. M., Bröcker, E., Goetz, R., & Rapp, U. R. (2004) · Journal of Carcinogenesis · doi:10.1186/1477-3163-3-6 · Cited by 325
“Recently, mutations in the BRAF gene, which is localized on chromosome 7, have been reported in melanoma [6,7].”
BackgroundResultInfluentialLi, L., Hou, J., Liu, X., Guo, Y., Wu, Y., Zhang, L., & Yang, Z. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.01.019 · Cited by 289
“The mutant BRAF genes were expressed in a majority of melanomas, suggesting an important role in melanocyte biology and disease pathology [4].”
BackgroundRahmani, M., Davis, E. M., Bauer, C., Dent, P., & Grant, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506551200 · Cited by 288
Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma
Yancovitz, M., Litterman, A., Yoon, J., Ng, E., Shapiro, R. L., Berman, R. S., Pavlick, A. C., Darvishian, F., Christos, P., Mazumdar, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029336 · Cited by 283
“These mutation rates are comparable to previously reported rates in melanoma [8,21,22,23,24,25,26,27].”
ResultYang, S., Farraye, F. A., Mack, C., Posnik, O., & O’Brien, M. J. (2004) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000141404.56839.6a · Cited by 286
“DNA from 10-µm paraffin-embedded sections of the entire polyp was harvested by a simple proteinase K digestion and boiling method without further purification as reported previously.11 Allele-specific PCR (AS-PCR) primers for detecting BRAF exon 15 codon 599 mutation as well as sequencing for BRAF exon 15 were identic…”
MethodWiesner, T., Murali, R., Fried, I., Cerroni, L., Busam, K., Kutzner, H., & Bastian, B. C. (2012) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3182498be5 · Cited by 279
New insight into BRAF mutations in cancer
Dhomen, N., & Marais, R. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.005 · Cited by 278
“These data show that BRAF is an oncogene that stimulates many of the hallmarks of cancer and yet, surprisingly, BRAF is mutated in up to 80% of the benign skin lesions called naevi [20,21,22] and in pre-malignant colon polyps [23,24].”
BackgroundBRAFE600 in benign and malignant human tumours
Michaloglou, C., Vredeveld, L. C. W., Mooi, W. J., & Peeper, D. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210704 · Cited by 275
“Like melanomas, naevi frequently harbour activating BRAF mutations (82%; Pollock et al., 2003).”
BackgroundWhiteman, D. C., Pavan, W. J., & Bastian, B. C. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00880.x · Cited by 273
“BRAF mutations are also commonly found in acquired melanocytic nevi (Pollock et al., 2002), and as these nevi tend to arise in the first two decades of life, it is likely that BRAF-mutant melanomas and nevi may be part of the same spectrum of melanocytic neoplasia.”
BackgroundThe Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Sheppard, K. E., & McArthur, G. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0259 · Cited by 265
“Similar to melanoma (60), benign nevi harbor activating mutations in BRAF (61) and, less frequently, NRAS (62).”
Background
Metadata
- Authors
- Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Kallioniemi, O., Hayward, N. K., Trent, J. M., & Meltzer, P. S.
- Affiliations
- National Institutes of Health (US)
- QIMR Berghofer Medical Research Institute (AU)
- The University of Western Australia (AU)
- Corresponding author
- Meltzer, Paul S.
- ORCID
- Venue
- Nature Genetics
- Published
- 2002-11-25
- Volume
- 33
- Issue
- 1
- Pages
- 19-20
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1565041471
- Cited by
- 1,730
- References
- 4
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 40 · 2023: 49 · 2022: 46 · 2021: 73 · 2020: 58 · 2019: 73 · 2018: 67 · 2017: 87 · 2016: 79 · 2015: 87 · 2014: 84 · 2013: 104 · 2012: 92
- FWCI
- 25.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- BRAF mutation, melanocytic nevi, melanoma, melanoma metastasis, RAS/MAPK pathway, carcinogenesis
- MeSH terms
- Cell Transformation, Neoplastic, DNA Mutational Analysis, Gene Frequency, Humans, Melanoma, Nevus, Signal Transduction, Polymerase Chain Reaction, Genetic Predisposition to Disease, Mutation, Missense, Oncogene Proteins v-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.